Agency Forms Undergoing Paperwork Reduction Act Review
| Published date | 23 February 2021 |
| Citation | 86 FR 10969 |
| Record Number | 2021-03556 |
| Section | Notices |
| Court | Centers For Disease Control And Prevention,Health And Human Services Department |
10969
Federal Register / Vol. 86, No. 34 / Tuesday, February 23, 2021 / Notices
Task Hourly rate Burden hours Labor cost
Total ...................................................................................................................................... ........................ ........................ 280,335,935
Staff believes that there are no current
start-up costs or other capital costs
associated with the Textile Rules.
Because the labeling of textile products
has been an integral part of the
manufacturing process for decades,
manufacturers have in place the capital
equipment necessary to comply with the
Rules’ labeling requirements. Industry
sources indicate that much of the
information required by the Textile Act
and Rules would be included on the
product label even absent their
requirements. Similarly, recordkeeping,
invoicing, and advertising disclosures
are tasks performed in the ordinary
course of business; therefore, covered
firms would incur no additional capital
or other non-labor costs as a result of the
Rules.
Request for Comments
Pursuant to Section 3506(c)(2)(A) of
the PRA, the FTC invites comments on:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information will have practical utility;
(2) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information, including the validity of
the methodology and assumptions used;
(3) ways to enhance the quality, utility,
and clarity of the information to be
collected; and (4) ways to minimize the
burden of maintaining records and
providing disclosures to consumers. All
comments must be received on or before
April 26, 2021.
You can file a comment online or on
paper. For the FTC to consider your
comment, we must receive it on or
before April 26, 2021. Write ‘‘Textile
Rules; PRA Comment: FTC File No.
P072108’’ on your comment. Your
comment—including your name and
your state—will be placed on the public
record of this proceeding, including the
https://www.regulations.gov website.
Due to the public health emergency in
response to the COVID–19 outbreak and
the agency’s heightened security
screening, postal mail addressed to the
Commission will be subject to delay. We
encourage you to submit your comments
online through the https://
www.regulations.gov website.
If you prefer to file your comment on
paper, write ‘‘Textile Rules; PRA
Comment: FTC File No. P072108’’ on
your comment and on the envelope, and
mail your comment to the following
address: Federal Trade Commission,
Office of the Secretary, 600
Pennsylvania Avenue NW, Suite CC–
5610 (Annex J), Washington, DC 20580;
or deliver your comment to the
following address: Federal Trade
Commission, Office of the Secretary,
Constitution Center, 400 7th Street SW,
5th Floor, Suite 5610 (Annex J),
Washington, DC 20024. If possible,
submit your paper comment to the
Commission by courier or overnight
service.
Because your comment will become
publicly available at https://
www.regulations.gov, you are solely
responsible for making sure that your
comment does not include any sensitive
or confidential information. In
particular, your comment should not
include any sensitive personal
information, such as your or anyone
else’s Social Security number; date of
birth; driver’s license number or other
state identification number, or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. You are also solely
responsible for making sure that your
comment does not include any sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, your comment should not
include any ‘‘trade secret or any
commercial or financial information
which .... is privileged or
confidential’’ —as provided by Section
6(f) of the FTC Act, 15 U.S.C. 46(f), and
FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)
—including in particular competitively
sensitive information such as costs,
sales statistics, inventories, formulas,
patterns, devices, manufacturing
processes, or customer names.
Comments containing material for
which confidential treatment is
requested must be filed in paper form,
must be clearly labeled ‘‘Confidential,’’
and must comply with FTC Rule 4.9(c).
In particular, the written request for
confidential treatment that accompanies
the comment must include the factual
and legal basis for the request, and must
identify the specific portions of the
comment to be withheld from the public
record. See FTC Rule 4.9(c). Your
comment will be kept confidential only
if the General Counsel grants your
request in accordance with the law and
the public interest. Once your comment
has been posted publicly at
www.regulations.gov, we cannot redact
or remove your comment unless you
submit a confidentiality request that
meets the requirements for such
treatment under FTC Rule 4.9(c), and
the General Counsel grants that request.
The FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding, as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before April 26, 2021. For information
on the Commission’s privacy policy,
including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/
site-information/privacy-policy.
Josephine Liu,
Assistant General Counsel for Legal Counsel.
[FR Doc. 2021–03604 Filed 2–22–21; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30-Day–21–0888]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Factors
Influencing the Transmission of
Influenza to the Office of Management
and Budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on October
13, 2020 to obtain comments from the
public and affected agencies. CDC
received two comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary for the
proper performance of the functions of the
agency, including whether the information
will have practical utility;
(b) Evaluate the accuracy of the agencies
estimate of the burden of the proposed
VerDate Sep<11>2014 18:36 Feb 22, 2021 Jkt 253001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\23FEN1.SGM 23FEN1
10970
Federal Register / Vol. 86, No. 34 / Tuesday, February 23, 2021 / Notices
collection of information, including the
validity of the methodology and assumptions
used;
(c) Enhance the quality, utility, and clarity
of the information to be collected;
(d) Minimize the burden of the collection
of information on those who are to respond,
including, through the use of appropriate
automated, electronic, mechanical, or other
technological collection techniques or other
forms of information technology, e.g.,
permitting electronic submission of
responses; and
(e) Assess information collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Factors Influencing the Transmission
of Influenza (OMB Control No. 0920–
0888, Exp. 2/28/21)—Extension—
National Institute for Occupational
Safety and Health (NIOSH), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The National Institute for
Occupational Safety and Health
(NIOSH) is authorized to conduct
research to advance the health and
safety of workers under Section 20(a)(1)
of the 1970 Occupational Safety and
Health Act. NIOSH is requesting an
extension to an existing ICR (Expiration
Date: February 28, 2021) because the
ongoing COVID–19 pandemic
temporarily halted the study in 2020
due to staff safety concerns and an
inability to access healthcare facilities
in order to recruit test subjects.
Influenza continues to be a major
public health concern because of the
substantial health burden from seasonal
influenza and the potential for a severe
pandemic. Although influenza is known
to be transmitted by infectious
secretions, these secretions can be
transferred from person to person in
many different ways, and the relative
importance of the different pathways is
not known. The likelihood of the
transmission of influenza virus by small
infectious airborne particles produced
during coughing and breathing is
particularly unclear. The question of
airborne transmission is especially
important in healthcare facilities, where
influenza patients tend to congregate
during influenza season, because it
directly impacts the infection control
and personal protective measures that
should be taken by healthcare workers.
The purpose of this study is to gain
a better understanding of the production
of infectious aerosols by patients with
influenza, and to compare this to the
levels of biomarkers of influenza
infection in the blood of these patients.
To do this, airborne particles produced
by volunteer subjects with influenza
will be collected and tested for
influenza virus, and the levels of
influenza infection-associated
biomarkers will be measured in blood
samples from these subjects.
Volunteer adult participants will be
recruited by a test coordinator using a
poster and flyers describing the study.
Interested potential participants will be
screened verbally to verify that they
have influenza-like symptoms and that
they do not have any medical
conditions that would preclude their
participation. A matching number of
healthy control participants will also be
recruited. Qualified participants who
agree to participate in the study will be
asked to read and sign an informed
consent form, and then to complete a
short health questionnaire. After
completing the forms, the participant’s
oral temperature will be measured and
two nasopharyngeal mucus samples and
five ml of blood will be collected. The
participant then will be asked to don an
elastomeric mask and breathe and cough
normally for 40 minutes into an aerosol
particle collection system. The total
time from initial verbal screening to
completion will be about 95 minutes.
The study will require 90 volunteer test
subjects each year for three years, for a
total of 270 test participants. There are
no changes to data collection
instruments, methodology, or burden
estimates. OMB approval is requested
for three years. Participation is
voluntary and there are no costs to
respondents other than their time. The
total estimated annualized burden hours
are 148.
E
STIMATED
A
NNUALIZED
B
URDEN
H
OURS
Type of respondents Form name Number of
respondents
Number of
responses per
respondent
Avg. burden
per response
(in hrs.)
Potential participant ........................................ Initial verbal screening ................................... 180 1 3/60
Qualified participant ........................................ Informed consent form ................................... 90 1 15/60
Qualified participant ........................................ Health questionnaire ...................................... 90 1 5/60
Qualified participant ........................................ Medical testing ............................................... 90 1 72/60
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–03556 Filed 2–22–21; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014 18:36 Feb 22, 2021 Jkt 253001 PO 00000 Frm 00052 Fmt 4703 Sfmt 9990 E:\FR\FM\23FEN1.SGM 23FEN1
